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Abstract
Background: This study is aimed at describing the prevalence of and risk factors associated with early post-operative com-
plications after Crohn’s disease-related intestinal resection.
Methods: This was a retrospective analysis of data from the PRACTICROHN cohort. Adult Crohn’s disease patients who
underwent ileocolonic resection with ileocolonic anastomosis between January 2007 and December 2010 were included.
The complications evaluated included death, ileus, anastomotic leak, abscess, wound infection, catheter-related infection,
digestive bleeding and other extra-abdominal infections that occurred in the 30 days after surgery.
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Results: A total of 364 patients (median age at surgery 38 years and 50% men) were included. Indication for surgery was:
stricturing disease (46.4%), penetrating disease (31.3%), penetrating and stricturing disease (14.0%) or resistance to medical
treatment (5.8%). Early complications were recorded in 100 (27.5%) patients, with wound infection, intra-abdominal abscess
and anastomotic leakage being the most frequent complications. Median hospitalization duration was 16 days for patients
with complications vs. 9 days without complications (P<0.001). Complications were more common among patients
with penetrating disease (36/114, 31.6%) and those refractory to treatment (9/21, 42.9%) compared with stricturing disease
(45/169, 26.6%) or stricturingþpenetrating disease (6/51, 11.8%) (P¼0.040). The rate of complications was higher among
patients with diagnosis made at the time of surgery (15/31, 48.4%) compared with the rest (85/331, 25.7%) (P¼0.013).
Medication received at the time of surgery did not affect the rate of complications.
Conclusions: Almost a quarter of patients developed early complications after intestinal resection. Penetrating disease and
urgent surgery were associated with an increased risk of complications.
Key words: Ileocolonic resection; Crohn’s disease; post-operative complications; risk factors
Introduction
Crohn’s disease (CD) is an inflammatory bowel disease (IBD)
that affects the ileum, colon or both and may involve other
parts of the gastrointestinal tract and/or have extra-intestinal
manifestations. It is a progressive, destructive and currently in-
curable condition that is more prevalent in Europe and North
America, where it affects between 10 and 150 in 100,000 per-
sons, with a higher prevalence in women than in men [1].
Treatment is aimed at achieving sustained clinical remission
and preventing cumulative tissue damage and subsequent
disease-related complications [2]. Medical treatment is the pri-
mary therapeutic approach [3], though surgical management is
essential in patients who fail to respond to medical therapy and
in those who present intra-abdominal abscesses, perianal or in-
ternal fistulas, bowel obstruction or cancer [4]. Intestinal resec-
tion rates in CD range between 19% and 61% in the first 5 years
after diagnosis and can reach 80% in the first 20 years after diag-
nosis, with recent studies suggesting a decline in the frequency of
surgery [5–8]. The risk factors for surgery in CD are current smok-
ing, penetrating and stricturing disease, early treatment with cor-
ticosteroids, ileal or jejunal disease and young age at diagnosis
[1, 9]. Relapses are common, with post-operative recurrence af-
fecting about 30% of patients despite prophylaxis [10]; approxi-
mately 14% of patients require re-intervention in the first 5 years
after surgery and 30% in the first 10 years after surgery [11].
Surgery is associated with post-operative complications
(POCs), the risk of which depends on several factors, such as dis-
ease pattern (perforating disease is associated with a higher risk
of POCs), type of anastomosis, surgeon’s experience, type of sur-
gery (elective vs. urgent, open vs. laparoscopic) and other fac-
tors [12]. The aim of our study was to describe the prevalence of
and the risk factors associated with early POCs (ePOCs) in a co-
hort of patients who underwent intestinal resection for CD.
Methods
Study design
We retrospectively reviewed the records of patients at 26
Spanish IBD units. No data were collected prospectively. The
study was approved by the corresponding Research Ethics
Committees.
Patient selection
We identified patients from IBD outpatient clinics aged more
than 18 years who underwent ileocolonic resection with
ileocolonic anastomosis for CD between January 2007 and
December 2010. Those who signed an informed consent autho-
rizing the use of their clinical data for research were included.
For this analysis, patients’ data from diagnosis of CD to the in-
dex surgery and until 5 years after the index surgery were col-
lected from medical records. All surgeries were performed with
anastomosis; no surgeries with stomas were included. When
the patient had undergone more than one procedure, the index
surgery was considered that closest to December 2010. Data col-
lected from the medical records included demographic data
(age, sex, smoking status and family history) and clinical data
(date of diagnosis, Montreal classification at diagnosis and at
time of surgery [13], extra-intestinal manifestations, immune-
mediated inflammatory diseases, IBD-related treatments re-
ceived before surgery [from diagnosis to surgery] and at the
time of surgery, approach [open or laparoscopic], previous
surgeries, reason for current surgery [penetrating or stricturing
disease or resistance to treatment], length of resection and hos-
pital stay). We evaluated the rate of ePOCs during the 30 days
after surgery, including death, ileus, anastomotic leak, digestive
bleeding, abscess, wound infection, catheter-related infection
and other extra-abdominal infections. We performed a separate
analysis of infectious complications (wound infections, intra-
abdominal abscesses, extra-abdominal infections and catheter-
related infections). Finally, we analyzed the number of surgeries
performed at each site during the study period and the influ-
ence of IBD drugs on ePOCs at the time of surgery. The rate of
post-operative recurrence in this sample of patients has been
reported elsewhere [10].
Statistical analysis
The sample size was calculated based on the primary endpoint
of the PRACTICROHN study, namely the rate of disease recur-
rence at 52 weeks after surgery, and has been published else-
where [10]. The t-test, analysis of variance or nonparametric
tests (Mann–Whitney test) were used to compare continuous
variables. Categorical variables were compared using the v2 test
or Fisher’s exact test, if needed.
Missing values and their frequency were tabulated but in-
cluded in calculating the percentages. In all cases, the distribu-
tion of variables according to theoretical models was verified
with the Kolmogorov–Smirnov test and the assumption of ho-
mogeneity of variance was contrasted using Levene’s test.
Logistic-regression analysis was performed to study which
baseline characteristics correlated with the variables of interest
(primary and secondary objectives). Models were compared
based on baseline clinical variables and surgical characteristics
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using a maximum-likelihood test, with an evaluation of possi-
ble interactions. Variables with P< 0.15 in the bivariate analysis
were selected for the multivariate analysis. Statistical signifi-
cance was set at P< 0.05.
Results
Baseline characteristics
Data from 364 CD patients were analyzed with a median age at
time of surgery of 38 years (interquartile range [IQR] 30–48).
The patients’ demographic and clinical characteristics are sum-
marized in Table 1. At the time of surgery, 90 (24.7%) patients
had been exposed to corticosteroids, 165 (45.3%) to
immunomodulators and 64 (17.6%) to biological treatments.
Median time of hospitalization was 10 days (interquartile range
[IQR] 7–14). After surgery, 27 patients had residual disease
(7.4%). All patients underwent open surgery, except for 2
patients who underwent laparoscopy (data available for 300
patients).
Early POCs
At least one ePOC was recorded in 100 patients (27.5%). Wound
infection (n¼ 33, 9.1%), intra-abdominal abscess (n¼ 28, 7.7%)
and anastomotic leak (n¼ 27, 7.4%) were the most common
ePOCs (Table 2). There were no deaths within 30 days after sur-
gery. Median hospital stay for patients with ePOCs was 16 days
(IQR 10–28) compared with 9 days (IQR 7–11) for patients without
ePOCs (p< 0.001). As for the experience of the centres in IBD-
related surgery, only 20 out of 26 centres had data on the num-
ber of IBD-related surgeries performed during 2007–10. We
Table 1. Patients’ demographic and clinical characteristics
Characteristic All patientsa (n¼ 364) Without ePOCs (n¼ 263) With ePOCs (n¼ 100) P-value
Male gender 182 (50.0) 126 (47.9) 55 (55.0) 0.276
Age at time of diagnosis, years 28 (22–39) 28 (22–38) 30 (24–44) 0.042
Time between diagnosis and surgery, years 6 (1–12) 7 (1–12) 5 (0.8–12) 0.197
Age at time of resection, years 38 (30–48) 37 (29–47) 39 (31–51) 0.119
Active smokers at time of resection 128 (35.2) 97 (36.9) 30 (30.0) 0.836
Number of previous surgeries 0.745
0 290 (79.7) 211 (80.2) 78 (78.0)
1 74 (20.3) 52 (19.8) 22 (22.0)
Location at time of resection 0.474
L1 6 L4 199 (54.7) 145 (55.1) 53 (53.0)
L2 6 L4 6 (1.6) 3 (1.1) 3 (3.0)
L3 6 L4 159 (43.7) 115 (43.7) 44 (44.0)
Behaviour at time of resection 0.883
B1 32 (8.8) 22 (8.4) 10 (10.0)
B2 184 (50.5) 134 (51.0) 50 (50.0)
B3 145 (39.8) 105 (39.9) 39 (39.0)
Perianal disease at time of resection 37 (10.2) 25 (9.5) 12 (12.0) 0.607
Perianal disease at any time during the disease 65 (17.9) 49 (18.6) 16 (16.0) 0.603
Length of resection 0.243
50 cm 248 (68.1) 177 (67.3) 71 (71.0)
>50 cm 38 (10.4) 23 (8.7) 15 (15.0)
Extra-intestinal manifestations between diagnosis and surgery 45 (12.4) 31 (11.8) 14 (14.0) 0.651
Indication for surgery 0.018
Penetrating 114 (31.3) 77 (29.3) 36 (36.0)
Stricturing 169 (46.4) 124 (47.1) 45 (45.0)
Penetrating þ stricturing 51 (14.0) 45 (17.1) 6 (6.0)
Resistance to treatment 21 (5.8) 12 (4.6) 9 (9.0)
Medication prior to surgery
Corticosteroids 174 (47.8) 134 (51.0) 39 (39.0) 0.043
Immunomodulators 73 (20.1) 57 (21.7) 16 (16.0) 0.305
Anti-TNF 68 (18.7) 51 (19.4) 17 (17.0) 0.736
More than 1 medication 81 (22.3) 62 (23.6) 19 (19.0) 0.379
Medication at the time of surgery
Corticosteroids 90 (24.7) 62 (23.6) 28 (28.0) 0.493
Immunomodulators 165 (45.3) 119 (45.2) 46 (46.0) 0.937
Anti-TNF 64 (17.6) 42 (16.0) 22 (22.0) 0.218
More than 1 medication 90 (24.7) 62 (23.6) 28 (28.0) 0.434
Time from diagnosis to surgery 0.013
<1 month 31 (8.5) 16 (6.1) 15 (15.0)
1 month 331 (90.9) 245 (93.2) 85 (85.0)
Length of hospitalization, days 10 (7–14) 9 (7–11) 16 (10–28) <0.001
ePOCs, early post-operative complications; TNF, tumour necrosis factor.
aThere is one patient with missing data regarding having ePOC or not.
Values presented as median (interquartile range) or number (%).
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found no difference in the rate of ePOCs related to the number
of surgeries performed in each hospital (32% in hospitals with
<30 surgeries, 25% in hospitals with 31–60 surgeries and 26% in
hospitals with >60 surgeries; P¼ 0.40). The only type of ePOC
that was more frequent in hospitals with a lower number of
IBD-related surgeries was anastomotic leak (15.2% in hospitals
with <30 surgeries performed vs. 5.9% in hospitals with 31–60
surgeries and 3.5% in hospitals with >60 surgeries; P¼ 0.001)
(Table 2).
There were no associations between the incidence of ePOCs
and the length of intestinal resection, sex, age at time of sur-
gery, history of previous surgeries, location of disease, presence
of perianal disease, disease behaviour or smoking status
(Table 1). Regarding treatments received before surgery, we
found that patients without ePOC more frequently received cor-
ticosteroids before surgery than patients with ePOC 39 (51.0%
vs. 39.0%, P¼ 0.043), with no difference in the rate of ePOCs
found with other treatments. Nevertheless, at the time of sur-
gery, we found no differences in the rate of ePOCs with any of
the treatments received (Table 1). The main reason for surgery
was stricturing disease, both in patients with ePOCs (45.0%) and
without ePOCs (47.1%); however, the incidence of ePOCs was
higher in patients with intestinal perforation as the indication
for surgery (36/114, 31.6%), as was being refractory to treatment
(9/21, 42.9%), than in those with stricturing disease (alone or in
combination with penetrating disease), which was associated
with a lower risk of ePOCs (45/169, 26.6% and 6/51, 11.8%, re-
spectively) (P¼ 0.040) (Figure 1). We also analyzed the relation-
ship between time from diagnosis to surgery and the presence
of ePOCs and found that ePOCs were more common in patients
with surgery performed in the month following the diagnosis of
CD (15/31, 48.4%) than in patients who were operated on when
the diagnosis of CD had been already established (85/331, 25.7%;
P¼ 0.013) (Figure 1).
Multiple logistic-regression analysis showed no association
between the risk of ePOCs and the following independent varia-
bles: age at time of surgery, sex, reason for surgery, emergency
surgery and number of surgeries performed at each site (Table 3).
Treatments prescribed at discharge and follow-up after sur-
gery are summarized in Table 4. Patients with ePOCs were pre-
scribed immunomodulators at discharge less frequently
(P¼ 0.025) and were monitored with imaging techniques (com-
puted tomography or magnetic resonance imaging) more fre-
quently (P¼ 0.047). No other differences were found regarding
Table 2. Number of patients with early post-operative complications (ePOCs)
Event All patients (n¼ 364) Number of IBD surgeries performed between 2007 and 2010
30 (n¼ 105) 31–60 (n¼ 85) >60 (n¼ 170) P-value
Any complication 100 (27.5)a 34 (32.4) 21 (24.7) 44 (25.9) 0.404
Death 0 (0) 0 (0) 0 (0) 0 (0) –
Ileus 11 (3.0) 6 (5.7) 1 (1.2) 3 (1.8) 0.122
Digestive bleeding 11 (3.0) 3 (2.9) 2 (2.4) 6 (3.5) 0.927
Anastomotic leak 27 (7.4) 16 (15.2) 5 (5.9) 6 (3.5) 0.001
Intra-abdominal abscess 28 (7.7) 11 (10.5) 5 (5.9) 12 (7.1) 0.446
Wound infection 33 (9.1) 10 (9.5) 6 (7.1) 17 (10.0) 0.737
Catheter-related sepsis 4 (1.1) 0 (0) 2 (2.4) 2 (1.2) 0.270
Other extra-abdominal infections 12 (3.3) 2 (1.9) 3 (3.5) 7 (4.1) 0.693
aThere is one patient with ePOC missing data regarding number of surgeries performed on this site.
Figure 1. Percentage of patients with and without early post-operative complications (ePOCs) according to cause for surgery and time from diagnosis to surgery. The
dotted lines correspond to the percentages of patients without and with ePOCs in the overall study population (68.4% and 31.6%, respectively).
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the treatments received or the follow-up between patients with
and without ePOCs.
Infectious complications
During the first month after surgery, 69 patients (19.0%) pre-
sented with at least one infectious complication; the median
length of hospital stay was 19 days (IQR 10–30) for patients with
infectious complications compared with 9 days (IQR 7–12) for
the remaining patients (P< 0.001). The most frequent infectious
complications were wound infections (n¼ 33), intra-abdominal
abscesses (n¼ 28), extra-abdominal infections (n¼ 12) and
catheter-related infections (n¼ 4). No differences in the inci-
dence of infectious complications were observed regarding age,
sex, smoking status, disease location or length of intestinal
resections. There was no association between medication re-
ceived at surgery and the rate of infectious complications.
Discussion
Surgery carries risks, including mortality and POCs. Serious
POCs, such as anastomotic leak and intra-abdominal sepsis, de-
velop more frequently after surgery for CD than other intestinal
resections [14, 15]. Incidence varies with the type of complica-
tion, as follows: 0%–18.8% for wound sepsis, 3.1%–18.7% for ab-
dominal abscess, 0%–12.7% for anastomotic leak [8, 16, 17] and
0.6%–3.6% for post-operative death [17].
In the present observational study, which was based on data
from routine practice in a large sample of patients from Spain,
we evaluated the rate of ePOCs following surgery for CD. We
found that 27.5% of patients developed ePOCs after intestinal re-
section, with wound infection, abscess and anastomotic leak be-
ing the most frequent complications. Our results are in line with
those of previous studies, which reported an incidence of ePOCs
of 15%–30% after bowel resection in patients with CD [18–21].
It is worth mentioning that hospital experience in IBD-
related surgery was not related to the rate of ePOCs, except for
anastomotic leak, which was more common in hospitals with
<30 surgeries performed between 2007 and 2010 than in hospi-
tals with >60 surgeries performed during the same time period
(P¼ 0.001). This finding is similar to that of previous studies,
where surgeon experience was associated with better outcomes
[22, 23]. In our study, most of the surgeries were performed by
specialized colorectal surgeons, thus explaining the low rate of
differences found.
Analysis of the risk factors for ePOCs revealed that surgery
performed at the time of diagnosis (probably an urgent surgery)
and stricturing disease as the indication for surgery were both
significantly associated in the bivariate analyses, with an in-
creased risk of complications, and penetratingþ stricturing dis-
ease (more specifically, perforation, data not shown) associated
with a lower risk. The potential impact of previous medication,
in particular, anti-tumour necrosis factor (TNF) drugs or cortico-
steroids, on the risk of ePOCs after bowel resection in CD is a
matter of debate. While some studies and meta-analyses sug-
gest that anti-TNF treatment before surgery is associated with a
higher rate of ePOCs, especially infectious complications [24–
26], others find no increased risk [20, 27, 28]. In our study, we
found no association between the risk of ePOCs and the use
Table 3. Logistic-regression results
Explicative variables Coefficient (95% confidence interval) Odds ratio Z-value P-value
Intercept –0.42 (–1.51, 0.67) 0.65 –0.760 0.447
Age at surgery 0.02 (0, 0.04) 1.02 1.818 0.069
Gender: female –0.30 (–0.8, 0.2) 0.74 –1.164 0.244
Indication for surgery: stricturing –0.16 (–0.72, 0.41) 0.86 –0.546 0.585
Indication for surgery: penetrating þ stricturing –1.05 (–2.1, –0.14) 0.35 –2.120 0.034
Indication for surgery: resistance to treatment 0.61 (–0.41, 1.62) 1.85 1.196 0.232
Number of surgeries performed at each site: 31–60 –0.29 (–0.98, 0.38) 0.75 –0.839 0.401
Number of surgeries performed at each site: >60 –0.26 (–0.82, 0.31) 0.77 –0.887 0.375
Time from diagnosis to surgery 1 month –0.90 (–1.7, –0.09) 0.41 –2.183 0.029
Table 4. Medication at discharge and follow-up after surgery
Treatment All patientsa (n¼ 364) Without ePOC (n¼ 263) With ePOC (n¼ 100) P-value
Medication at discharge
Oral corticosteroids 70 (19.2) 47 (17.9) 23 (23.0) 0.364
Immunomodulators 117 (32.1) 94 (35.7) 23 (23.0) 0.025
Antibiotics 77 (21.2) 52 (19.8) 25 (25.0) 0.324
Anti-TNF 31 (8.5) 19 (7.2) 12 (12.0) 0.213
Aminosalicylates 43 (11.8) 32 (12.2) 11 (11.0) 0.881
More than 1 medication 79 (21.7) 59 (22.4) 20 (20.0) 0.722
Follow-up after surgery
Days until the following visit 46.9 6 59.9 45.8 6 52.1 46.2 6 68.4 0.992
Colonoscopy in the first year 140 (38.5) 102 (38.8) 38 (38.0) 0.987
Imaging technique in the first year 59 (16.2) 36 (13.7) 23 (23.0) 0.047
Blood test in the first year 300 (82.4) 214 (81.4) 86 (86.0) 0.376
Biomarker test in the first year 44 (12.1) 30 (11.4) 14 (14.0) 0.620
ePOCs, early post-operative complications; TNF, tumour necrosis factor.
aThere is one patient with missing data regarding having ePOC or not.
Values presented as mean 6 standard deviation or number (%).
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of anti-TNF drugs. In that sense, the number of patients receiv-
ing anti-TNF treatment at surgery 64 (17.6%) is similar to the
study of Colombel et al. [29], with 19% of patients receiving anti-
TNF treatment at surgery. In Colombel’s study, no difference
was found either in the number of patients presenting ePOC be-
tween those with and without anti-TNF treatment at surgery.
During the study period, no other biologics were allowed for CD
treatment, hence no comparisons with vedolizumab could be
made. A comparison with vedolizumab would have been inter-
esting, given that treatment with this agent, which targets a4b7
integrin, has been associated with a greater risk of ePOCs (53%)
than treatment with TNF inhibitors (33%) or no biological thera-
pies (28%) [30].
Several observational studies identified pre-operative corti-
costeroid treatment as a risk factor for POCs [28, 31, 32]; how-
ever, high-quality studies on the subject are lacking. We found
that treatment with corticosteroids at the time of surgery was
not associated with a higher risk of early POCs. Though the
number of patients may have been insufficient to detect differ-
ences, we concomitantly found that corticosteroid use before
surgery was associated with a lower rate of ePOCs. This could
be explained by the fact that, while, during the treatment, 47.8%
of patients received treatment with corticosteroids, at the exact
time point of the surgery, only 24.7% of patients were receiving
treatment with steroids. That reflects an important withdrawal
of corticosteroid use and the patients who remained on cortico-
steroids likely used the minimum dose possible. Unfortunately,
we did not collect information on the dose of corticosteroid
used, so we cannot assure this point.
Other factors have been linked to POCs after CD-related in-
testinal resection. Thus, several studies and meta-analyses fo-
cused on the surgical approach and technique: 3 meta-analyses
of up to 15 studies showed the post-operative benefits of the
laparoscopic approach [33–35], including a decreased rate of
POCs and shorter hospital stay, faster return to normal activity
and diet, better cosmesis and improved social and sexual inter-
action. Another meta-analysis concluded that stapled side-to-
side anastomosis was linked to fewer overall POCs and a lower
recurrence and re-operation rate than end-to-end hand-sewn
anastomosis [36]. In our sample, only two patients underwent
laparoscopy, thus implying that our results only apply to open
abdominal surgery. Furthermore, since information on the type
of anastomosis was not collected in our study, we cannot com-
pare the frequencies of ePOC associated with the different tech-
niques. Given that the laparoscopic approach is widely used in
Spain today, the prevalence of ePOCs would probably be lower
than that reported in this analysis.
Emergency surgery is seldom necessary in CD. However,
when required, it is associated with higher rates of post-oper-
ative mortality (3.6%; 95% confidence interval [CI], 1.8%–6.9%)
than elective surgery (0.6%; 95% CI, 0.2%–1.7%) [17]. We recorded
no POC-related deaths, but 31 (8.5%) patients underwent surgery
within 1 month of the diagnosis of CD, probably reflecting a
more severe and complex disease, or emergency surgeries. In
these patients, the number of ePOCs was significantly higher
than in patients who had undergone surgery at least 1 month
after the diagnosis. Although we cannot rule out the possibility
that there were no emergency procedures in the latter group of
patients, our data agree with previous reports that associate
emergency surgery with an increased risk of POCs [37] and
stress the importance of the surgeon’s experience for better
outcomes.
Observational studies like this one use statistical methods to
identify risk factors; however, the results are more difficult to
compare due to differences in study design, available informa-
tion and possible confounding effects. Thus, in an observational
study of 131 patients with CD, Heimann et al. [18] found that
30% experienced complications early after surgical intervention
and septic complications were more common in patients with
extensive resections and in those with multiple previous opera-
tions. In our study, there was no statistically significant associa-
tion between length of resection and risk of POCs, though there
was a trend toward a higher incidence of ePOCs among patients
with extensive resections (>50 cm). We found no additional risk
of ePOCs associated with a history of previous surgeries, but the
number of patients with repeat surgeries was low. A total of 74
patients had previously undergone surgery (one procedure in
70, two procedures in 2 and three procedures in 3). The number
of patients with previous surgeries may have been insufficient
to detect significant differences in ePOCs between them and the
patients who underwent primary surgery.
In an observational study on 161 consecutive patients with
CD, Alves et al. [38] found that pre-operative corticosteroids,
poor nutritional status and the presence of abscess at the time
of surgery significantly increased the risk of septic abdominal
complications after the first ileocecal resection for CD.
Similarly, in a pooled analysis of 343 patients who underwent
566 operations for primary or recurrent CD, Yamamoto et al. [39]
found that intra-abdominal septic complications were signifi-
cantly associated with low pre-operative albumin levels (<30 g/L),
pre-operative corticosteroids and abscess or fistula at the time
of laparotomy. In the present sample, as mentioned above,
therapy with corticosteroids at the time of surgery was not as-
sociated with a higher risk of POCs, whereas perforation was.
Unfortunately, we recorded no data on nutritional status or al-
bumin levels at the time of surgery. Consistently with our
results, Yamamoto et al. found that age, duration of symptoms,
number of previous bowel resections and site of disease had no
effect on the risk of infectious complications. In contrast, in a
large study of 2638 patients with CD and 559 patients with
ulcerative colitis, Frolkis et al. [37] reported that predictors for
in-hospital POCs for both diseases included older age, comor-
bidities, open laparotomy for CD, emergency admission, stoma
surgery and concurrent resection of both the small and the
large bowels. Further, well-designed, large studies with wide-
ranging data are needed to better characterize the risk factors
associated with POC in CD-related bowel resection.
Our study presents a series of limitations. First, owing to
its retrospective design, the only data available were those
from patients’ medical records. Several relevant variables
were not collected, including type of anastomosis (stapled vs.
hand-sewn), configuration of anastomosis (end-to-end vs. side-
to-side), patients’ nutritional status, serum albumin levels,
creatinine levels and microscopically positive resection margin,
which have been recognized as risk factors for complications.
Second, the complications were not classified, such as using the
Clavien–Dindo classification [40]. As a result, we can only draw
conclusions about the scope of the complications but not about
their severity or impact on the patient beyond length of hospital
stay. Third, the insufficient size of certain subgroups of patients
may have hindered the detection of differences and precluded
the identification of additional risk factors for POCs. Finally,
analysing surgeries between 2007 and 2010 may not accurately
reflect current management of CD, though the choice of these
dates for the index surgeries did allow us to assess long-term out-
comes, such as recurrence and hospital admissions over 5 years
of follow-up after surgery. The study reflects clinical practice dur-
ing the years when the surgeries were performed and, although
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clinical practice has evolved since then, our findings highlight
the importance of ePOC as an event leading to longer hospital
stay and thus potentially higher related health-care costs.
In conclusion, one-quarter of patients who underwent ileo-
colonic resection for CD experienced ePOCs. The indication for
surgery and emergency surgery were the most important pre-
dictors of ePOCs.
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